Tofacitinib Citrate API for Prepare Preparation-Related Products

The chemical system name for tofacitinib (tofacitinib citrate) is 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]] Pyrimidine-4-yl)-piperidin-1-yl]-3-oxo-propionitrile citrate, a Janus kinase inhibitor developed by Pfizer. On November 6, 2012, the U.S. Food and Drug Administration (FDA) approved this substance as a drug for the treatment of moderately to severely active rheumatoid arthritis (RA) with insufficient response or intolerance to methotrexate therapy. Treatment of adult patients. Uses Tofacitinib is indicated for adults with moderately to severely active rheumatoid arthritis (RA) who are ineffective or intolerable to methotrexate. Combined use of rheumatic drugs (DMARDs). Tofacitinib citrate Tofacitinib citrate is a drug developed by Pfizer for the treatment of rheumatoid arthritis, trade name Xeljanz, for moderate to severe patients with insufficient response or intolerance to methotrexate treatment Active rheumatoid arthritis (RA) in adults. This product is a Janus kinase inhibitor and is taken twice daily. On November 6, 2012, the U.S. Food and Drug Administration (FDA) and Pfizer jointly announced that tofacitinib citrate was approved for moderately to severely active rheumatoid joints that have had an inadequate response or intolerance to methotrexate therapy. inflammatory disease (RA) in adult patients.